NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects

benzinga.com/general/biotech/25/02/43919925/nhs-englands-transition-from-biogens-drug-to-sandozs-biosimilar-sparks-alarm-as-multiple-sclerosi

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side effects.
At Charing Cross Hospital in London, about 170 multiple sclerosis patients…

This story appeared on benzinga.com, 2025-02-24 17:39:33.
The Entire Business World on a Single Page. Free to Use →